Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0442)
Name |
L-F001
|
||||
---|---|---|---|---|---|
Drug Type |
Others
|
Full List of Ferroptosis Target Related to This Drug
Prostaglandin G/H synthase 2 (PTGS2)
In total 1 item(s) under this Target | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
Target for Ferroptosis | Marker | |||
Responsed Disease | Cerebral ischemia | ICD-11: 8B10 | ||
Responsed Regulator | Mitogen-activated protein kinase 8 (MAPK8) | Driver | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | |||
In Vitro Model | HT22 cells | Normal | Mus musculus | CVCL_0321 |
Response regulation | L-F001 could restore GPX4 and glutamate-cysteine ligase modifier subunit (GCLM) levels, and significantly deceased Cyclooxygenase (COX-2) levels to rescue the lipid peroxidation imbalance. And L-F001 could reduce RSL3-induced c-Jun N-terminal kinase (JNK) activation, which might be a potential drug target for for the therapy of ferroptosis-related diseases, such as cerebral ischemia. | |||
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
In total 1 item(s) under this Target | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
Target for Ferroptosis | Suppressor | |||
Responsed Disease | Cerebral ischemia | ICD-11: 8B10 | ||
Responsed Regulator | Mitogen-activated protein kinase 8 (MAPK8) | Driver | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | |||
In Vitro Model | HT22 cells | Normal | Mus musculus | CVCL_0321 |
Response regulation | L-F001 could restore GPX4 and glutamate-cysteine ligase modifier subunit (GCLM) levels, and significantly deceased Cyclooxygenase (COX-2) levels to rescue the lipid peroxidation imbalance. And L-F001 could reduce RSL3-induced c-Jun N-terminal kinase (JNK) activation, which might be a potential drug target for for the therapy of ferroptosis-related diseases, such as cerebral ischemia. | |||
Glutamate--cysteine ligase regulatory subunit (GCLM)
In total 1 item(s) under this Target | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
Target for Ferroptosis | Suppressor | |||
Responsed Disease | Cerebral ischemia | ICD-11: 8B10 | ||
Responsed Regulator | Mitogen-activated protein kinase 8 (MAPK8) | Driver | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | |||
In Vitro Model | HT22 cells | Normal | Mus musculus | CVCL_0321 |
Response regulation | L-F001 could restore GPX4 and glutamate-cysteine ligase modifier subunit (GCLM) levels, and significantly deceased Cyclooxygenase (COX-2) levels to rescue the lipid peroxidation imbalance. And L-F001 could reduce RSL3-induced c-Jun N-terminal kinase (JNK) activation, which might be a potential drug target for for the therapy of ferroptosis-related diseases, such as cerebral ischemia. | |||